MDWD
MediWound Ltd.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Sell
-24/100
Last price
13.15
▼ 0.36 (2.66%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
13.51
Day high
13.53
Day low
13.10
Volume
58.78K
Market cap
$169.77M
P/E (TTM)
—
52W range
12.52 – 20.03
Trailing performance
Returnvs SPY
1W
-4.71%
-6.7%
1M
-1.05%
-2.2%
3M
-10.54%
-15.1%
6M
-22.51%
-40.7%
YTD
-28.76%
-43.0%
1Y
-23.50%
-39.9%
3Y
+23.59%
-58.7%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on MDWD open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
+8.86K
Net buying
Buy transactions
5
15.21K shares
Sell transactions
2
6.35K shares
Net transactions
+7
Buys less sells
Sell : buy shares
0.4 : 1
Mixed
Insider-held shares
2.16M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Sep 1, 26 | RUBINSTEIN SAMUEL Director |
SELL | 525 | $6.68K | Indirect |
| Sep 1, 26 | RUBINSTEIN SAMUEL Director |
BUY | 525 | $6.63K | Indirect |
| Aug 27, 26 | HESS SHMUEL Chief Operating Officer |
SELL | 5.82K | $75.39K | Direct |
| Aug 26, 26 | HESS SHMUEL Chief Operating Officer |
CONVERSION | 5.00K | $63.50K | Direct |
| Jun 3, 26 | SHAMIR NACHUM Director |
BUY | 6.00K | $84.00K | Direct |
| Jun 1, 26 | FOX DAVID MORTON Director |
BUY | 3.54K | $49.90K | Direct |
| May 29, 26 | RUBINSTEIN SAMUEL Director |
BUY | 150 | $2.15K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
FOX DAVID MORTON |
Director | 23.03K | Purchase |
HESS SHMUEL |
Chief Operating Officer | 10.09K | Sale |
RUBINSTEIN SAMUEL |
Director | — | Sale |
SHAMIR NACHUM |
Director | 57.02K | Purchase |
Fundamentals
Market cap$169.77M
Enterprise value$143.03M
Revenue (TTM)$11.86M
Gross profit$1.83M
EBITDA$-30.75M
Net income$-20.18M
EPS (TTM)$-2.17
Free cash flow$-29.05M
Total cash$35.34M
Total debt$8.61M
Book value / share$2.76
Shares outstanding12.91M
Float8.87M
Short % of float16.04%
Dividend yield0.00%
Beta (5Y)0.09
Valuation & profitability ratios
Trailing P/E—
Forward P/E-5.74
PEG ratio—
Price / sales—
Price / book4.76
EV / revenue12.06
EV / EBITDA-4.65
Gross margin15.46%
Operating margin-305.89%
Profit margin-170.10%
Return on equity-72.37%
Return on assets-28.59%
Debt / equity24.14
Current ratio2.32
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $16.96M | $20.22M | $18.69M | $26.50M | -16.1% |
| Operating revenue | $16.96M | $20.22M | $18.69M | $26.50M | -16.1% |
| Cost of revenue | $13.71M | $17.59M | $15.11M | $13.33M | -22.1% |
| Gross profit | $3.25M | $2.63M | $3.58M | $13.16M | +23.5% |
| Research & development | $14.32M | $8.88M | $7.47M | $10.18M | +61.3% |
| Selling, general & admin | $13.93M | $12.91M | $11.38M | $10.37M | +7.9% |
| Total operating expense | $28.53M | $22.02M | $19.08M | $20.83M | +29.6% |
| Operating income | -$25.28M | -$19.38M | -$15.50M | -$7.66M | -30.4% |
| Net interest income | $816.00K | -$35.00K | $1.10M | -$2.26M | +2,431.4% |
| Pre-tax income | -$23.71M | -$30.16M | -$6.53M | -$19.52M | +21.4% |
| Tax provision | $169.00K | $61.00K | $185.00K | $78.00K | +177.0% |
| Net income | -$23.88M | -$30.22M | -$6.72M | -$19.60M | +21.0% |
| Net income to common | -$23.88M | -$30.22M | -$6.72M | -$19.60M | +21.0% |
| Basic EPS | -2.10 | -3.03 | -0.75 | -3.93 | +30.7% |
| Diluted EPS | -2.10 | -3.03 | -0.75 | -3.93 | +30.7% |
| EBIT | -$23.33M | -$29.41M | -$6.10M | -$19.52M | +20.7% |
| EBITDA | -$21.47M | -$27.93M | -$4.80M | -$18.25M | +23.1% |
| Basic shares | 11.38M | 9.96M | 9.01M | 4.99M | +14.2% |
| Diluted shares | 11.38M | 9.96M | 9.01M | 4.99M | +14.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $4.80M | $9.15M | $11.87M | $33.90M | -47.6% |
| Cash & short-term investments | $53.14M | $43.16M | $11.87M | $33.90M | +23.1% |
| Accounts receivable | $1.62M | $4.80M | $3.70M | $9.33M | -66.2% |
| Inventory | $4.09M | $2.69M | $2.85M | $1.96M | +52.0% |
| Total current assets | $59.96M | $52.16M | $49.70M | $45.84M | +15.0% |
| Property, plant & equipment | $25.79M | $20.80M | $15.93M | $3.58M | +24.0% |
| Goodwill & intangibles | $33.00K | $99.00K | $165.00K | $231.00K | -66.7% |
| Total assets | $86.25M | $73.50M | $66.46M | $50.02M | +17.4% |
| Total current liabilities | $25.71M | $26.54M | $18.13M | $12.06M | -3.1% |
| Total debt | $8.15M | $6.51M | $6.35M | $846.00K | +25.2% |
| Total liabilities | $42.62M | $42.34M | $34.86M | $39.10M | +0.7% |
| Retained earnings | -$228.93M | -$205.05M | -$174.82M | -$168.11M | -11.6% |
| Shareholder equity | $43.63M | $31.15M | $31.59M | $10.91M | +40.1% |
| Working capital | $34.26M | $25.62M | $31.57M | $33.78M | +33.7% |
| Net tangible assets | $43.60M | $31.05M | $31.43M | $10.68M | +40.4% |
| Shares issued | 12.84M | 10.79M | 9.22M | 7.24M | +18.9% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$23.88M | -$30.22M | -$6.72M | -$19.60M | +21.0% |
| Depreciation & amortisation | $1.86M | $1.48M | $1.30M | $1.27M | +25.4% |
| Stock-based compensation | $3.11M | $3.14M | $1.94M | $1.95M | -1.0% |
| Change in working capital | $4.77M | $1.27M | $2.34M | -$7.24M | +275.4% |
| Operating cash flow | -$16.12M | -$13.62M | -$10.46M | -$11.88M | -18.3% |
| Capital expenditure | -$5.50M | -$6.27M | -$6.46M | -$555.00K | +12.2% |
| Investing cash flow | -$17.95M | -$8.40M | -$34.32M | -$481.00K | -113.8% |
| Financing cash flow | $29.62M | $19.39M | $22.92M | $35.76M | +52.7% |
| Free cash flow | -$21.63M | -$19.90M | -$16.93M | -$12.44M | -8.7% |
| End cash position | $4.80M | $9.15M | $11.87M | $33.90M | -47.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $3.09M | $1.48M | $1.87M | $5.43M | $5.71M | +109.6% |
| Operating revenue | $3.09M | $1.48M | $1.87M | $5.43M | $5.71M | +109.6% |
| Cost of revenue | $2.75M | $1.15M | $1.59M | $4.53M | $4.37M | +139.1% |
| Gross profit | $337.00K | $323.00K | $278.00K | $896.00K | $1.34M | +4.3% |
| Research & development | $5.90M | $5.18M | $4.48M | $3.46M | $3.49M | +13.8% |
| Selling, general & admin | $3.89M | $3.56M | $3.33M | $3.96M | $3.57M | +9.5% |
| Total operating expense | $9.79M | $8.30M | $8.09M | $7.42M | $7.06M | +18.0% |
| Operating income | -$9.46M | -$7.98M | -$7.81M | -$6.53M | -$5.72M | -18.5% |
| Net interest income | $2.10M | $5.01M | -$50.00K | $3.93M | -$7.56M | -58.1% |
| Pre-tax income | -$7.36M | -$2.97M | -$7.11M | -$2.60M | -$13.28M | -147.9% |
| Tax provision | $33.00K | -$17.00K | $73.00K | $53.00K | $38.00K | +294.1% |
| Net income | -$7.39M | -$2.95M | -$7.18M | -$2.65M | -$13.32M | -150.4% |
| Net income to common | -$7.39M | -$2.95M | -$7.18M | -$2.65M | -$13.32M | -150.4% |
| Basic EPS | -0.57 | -0.23 | -0.56 | -0.24 | -1.23 | -147.8% |
| Diluted EPS | -0.77 | -0.23 | -0.56 | -0.24 | -1.23 | -234.8% |
| EBIT | -$9.46M | -$7.98M | -$5.86M | -$6.53M | -$5.72M | -18.5% |
| EBITDA | -$9.06M | -$7.60M | -$5.17M | -$6.11M | -$5.32M | -19.1% |
| Basic shares | 12.88M | 12.87M | 12.83M | 11.02M | 10.84M | +0.1% |
| Diluted shares | 13.21M | 12.87M | 12.83M | 11.02M | 10.84M | +2.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | $4.80M | — | — | — |
| Cash & short-term investments | $35.34M | $44.65M | $53.14M | $59.09M | $32.44M | -20.8% |
| Accounts receivable | $3.49M | $2.75M | $1.62M | $6.04M | $6.80M | +27.1% |
| Inventory | $4.12M | $4.77M | $4.09M | $4.41M | $3.84M | -13.7% |
| Total current assets | $42.95M | $52.17M | $59.96M | $69.53M | $43.08M | -17.7% |
| Property, plant & equipment | $28.39M | $27.33M | $25.79M | $24.38M | $23.37M | +3.9% |
| Goodwill & intangibles | $0 | $17.00K | $33.00K | $50.00K | $66.00K | -100.0% |
| Total assets | $71.88M | $79.98M | $86.25M | $94.42M | $67.00M | -10.1% |
| Total current liabilities | $18.54M | $21.65M | $25.71M | $26.25M | $29.07M | -14.3% |
| Total debt | $8.61M | $8.13M | $8.15M | $8.27M | $8.07M | +5.9% |
| Total liabilities | $36.23M | $38.56M | $42.62M | $44.27M | $46.88M | -6.0% |
| Retained earnings | — | — | -$228.93M | — | — | — |
| Shareholder equity | $35.64M | $41.42M | $43.63M | $50.16M | $20.12M | -14.0% |
| Working capital | $24.41M | $30.52M | $34.26M | $43.28M | $14.01M | -20.0% |
| Net tangible assets | $35.64M | $41.41M | $43.60M | $50.11M | $20.05M | -13.9% |
| Shares issued | 12.91M | 12.85M | 12.84M | 12.82M | 10.88M | +0.5% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$7.39M | -$2.95M | -$7.18M | -$2.65M | -$13.32M | -150.4% |
| Depreciation & amortisation | $402.00K | $378.00K | $690.00K | $418.00K | $394.00K | +6.3% |
| Stock-based compensation | $755.00K | $644.00K | $662.00K | $740.00K | $862.00K | +17.2% |
| Change in working capital | -$622.00K | $756.00K | $3.63M | $2.30M | -$1.10M | -182.3% |
| Operating cash flow | -$9.13M | -$6.75M | -$3.02M | -$3.24M | -$5.76M | -35.1% |
| Capital expenditure | -$1.07M | -$1.82M | -$2.45M | -$1.04M | -$1.05M | +41.0% |
| Investing cash flow | -$2.39M | $17.76M | -$23.89M | $4.38M | $4.91M | -113.5% |
| Financing cash flow | $402.00K | -$421.00K | -$1.09M | $30.52M | $549.00K | +195.5% |
| Free cash flow | -$10.20M | -$8.57M | -$5.47M | -$4.28M | -$6.80M | -19.0% |
| End cash position | $4.34M | $15.35M | $4.80M | $32.74M | $1.06M | -71.7% |
Options analytics
Put / call volume
9.80
Put-heavy session
Put / call open interest
10.00
Positioning, not flow
Max pain
13.00
-1.1% from spot
ATM implied vol
12.5%
Nearest strike to spot
Skew (10% OTM)
0.0%
Calls bid over puts
Call volume
5
Contracts, this expiry
Put volume
49
Contracts, this expiry
Heaviest call OI
14.00
5 contracts
Heaviest put OI
13.00
30 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.77 | -0.57 | +26.0% |
| Mar 2026 | -0.66 | -0.23 | +65.3% |
| Dec 2025 | -0.61 | -0.56 | +8.5% |
| Sep 2025 | -0.83 | -0.24 | +71.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.73 | 5 | $6.73M | +23.9% |
| Next quarter | -0.66 | 5 | $12.51M | +570.1% |
| Current year | -2.23 | 5 | $23.67M | +39.6% |
| Next year | -2.29 | 5 | $31.81M | +34.3% |
Analyst targets & ownership
Mean target$30.67
High target$36.00
Low target$25.00
Implied upside133.21%
Analyst count6
ConsensusSTRONG BUY
Strong buy / Buy1 / 5
Hold0
Sell / Strong sell0 / 0
Held by insiders16.71%
Held by institutions55.88%
Institutions holding112
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
13.66
-3.73% from price
SMA 20
13.59
-3.25% from price
SMA 50
13.58
-3.15% from price
SMA 100
14.16
-7.14% from price
SMA 200
15.77
-16.61% from price
EMA 12
13.55
-2.96% from price
EMA 26
13.55
-2.96% from price
EMA 50
13.71
-4.08% from price
RSI (14)
42.3
Neutral
MACD (12,26,9)
-0.00
Hist -0.03
ATR (14)
0.39
2.99% of price
Realised vol 30D
38.0%
Annualised
Bollinger upper
14.11
20, 2σ
Bollinger lower
13.07
20, 2σ
50 / 200 cross
Death
13.58 vs 15.77
Trend bias
Below 200
-16.61%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.60
Less volatile than market
Correlation to SPY
0.20
Largely independent
Realised vol 30D
38.0%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-36.0%
Peak to trough
Max drawdown 5Y
-74.4%
Peak to trough
ATR 14
0.39
2.99% of price
Beta (reported)
0.09
5Y monthly, from filing
Short interest
Shares short
1.81M
Prior 1.59M
Change vs prior
+14.2%
Shorts adding
% of float
16.04%
Elevated
% of shares out
14.05%
Against total outstanding
Days to cover
15.0
Crowded exit
Float
8.87M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 14, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 28, 26 | Oppenheimer | MAINTAINED | Outperform | Outperform |
| May 28, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 21, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 22, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Mar 20, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 28, 25 | Craig-Hallum | INITIATED | — | Buy |
| Jan 10, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Nov 27, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Oct 11, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 15, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Jul 16, 24 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:7
Split dateDec 20, 2022
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-13
Corporate Changes & Voting Matters
6-K · 2026-05-27
Corporate Changes & Voting Matters
6-K · 2026-05-06
Corporate Changes & Voting Matters
6-K · 2026-04-02
Corporate Changes & Voting Matters
6-K · 2026-03-30
Periodic Financial Reports
20-F · 2026-03-05
Corporate Changes & Voting Matters
6-K · 2026-02-19
Corporate Changes & Voting Matters
6-K · 2026-01-15
Headlines
MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
GlobeNewswire · 15d ago
Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
GlobeNewswire · 23d ago
MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · 35d ago
MediWound (MDWD) Q2 2026 Earnings Call Transcript
Motley Fool · 48d ago
Oppenheimer Adjusts Price Target on MediWound to $30 From $32, Keeps Outperform Rating
MT Newswires · 54d ago
MediWound Ltd. Q2 2026 Earnings Call Summary
Moby · 54d ago
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ...
GuruFocus.com · 55d ago
MediWound Q2 Earnings Call Highlights
MarketBeat · 55d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.